
Ruediger E Port

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11301090/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Estimating kinetic parameters from dynamic contrast-enhanced t1-weighted MRI of a diffusable tracer: Standardized quantities and symbols. Journal of Magnetic Resonance Imaging, 1999, 10, 223-232.	3.4	2,856
2	Dynamic contrast-enhanced MRI using Gd-DTPA: Interindividual variability of the arterial input function and consequences for the assessment of kinetics in tumors. Magnetic Resonance in Medicine, 2001, 45, 1030-1038.	3.0	147
3	Multicompartment analysis of gadolinium chelate kinetics: Blood-tissue exchange in mammary tumors as monitored by dynamic MR imaging. Journal of Magnetic Resonance Imaging, 1999, 10, 233-241.	3.4	145
4	An automated method for nonparametric kinetic analysis of clinical DCEâ€MRI data: Application to glioblastoma treated with bevacizumab. Magnetic Resonance in Medicine, 2010, 63, 1366-1375.	3.0	33
5	Noncompartmental kinetic analysis of DCEâ€MRI data from malignant tumors: Application to glioblastoma treated with bevacizumab. Magnetic Resonance in Medicine, 2010, 64, 408-417.	3.0	30
6	Erythropoietin dosing in children with chronic kidney disease: based on body size or on hemoglobin deficit?. Pediatric Nephrology, 2009, 24, 435-437.	1.7	28
7	Recombinant Human Erythropoietin for the Treatment of Renal Anaemia in Children. Clinical Pharmacokinetics, 2004, 43, 57-70.	3.5	26
8	Noninvasive methods to study drug distribution. Investigational New Drugs, 2003, 21, 157-168.	2.6	20
9	Simultaneous sustained release of fludarabine monophosphate and Gd-DTPA from an interstitial liposome depot in rats: potential for indirect monitoring of drug release by magnetic resonance imaging. Cancer Chemotherapy and Pharmacology, 2006, 58, 607-617.	2.3	20
10	Mixedâ€effects modeling of clinical DCEâ€MRI data: Application to colorectal liver metastases treated with bevacizumab. Journal of Magnetic Resonance Imaging, 2015, 41, 132-141.	3.4	9